Targeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
Authors:
- Tzu-Chieh HoTzu-Chieh Ho
- Mark W. LaMereMLMark W. LaMere
- Hiroki KawanoHKHiroki Kawano
- Elizabeth A. LaMereELElizabeth A. LaMere
- Yu-Chiao ChiuYCYu-Chiao Chiu
- Chunmo ChenCCChunmo Chen
- Jian WangJWJian Wang
- Nikolay V. DokholyanNDNikolay V. Dokholyan
- Laura M. CalviLCLaura M. Calvi
- Jane L. LiesveldJLJane L. Liesveld
- Craig T. JordanCJCraig T. Jordan
Preprint
Abstract
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.Keywords
All Related Versions
- Published version: Leukemia, 40 (2), 293.
This publication has 53 references indexed in Scilit:
- Treatment of Relapsed Acute Myeloid LeukemiaCurrent Treatment Options in Oncology, 2020
- Toll-like Receptors and the Control of ImmunityCell, 2020
- Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromesBlood Reviews, 2019
- MedusaDock 2.0: Efficient and Accurate Protein–Ligand Docking With ConstraintsJournal of Chemical Information and Modeling, 2019
- Coral: Clear and Customizable Visualization of Human Kinome DataCell Systems, 2018
- Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaCell Reports, 2017
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic SyndromeCancer Cell, 2013
- Gene Sets Identified with Oncogene Cooperativity Analysis Regulate In Vivo Growth and Survival of Leukemia Stem CellsCell Stem Cell, 2012
- Rapid Flexible Docking Using a Stochastic Rotamer Library of LigandsJournal of Chemical Information and Modeling, 2010
- MedusaScore: An Accurate Force Field-Based Scoring Function for Virtual Drug ScreeningJournal of Chemical Information and Modeling, 2008